Does Amylyx Pharmaceuticals, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Amylyx Pharmaceuticals, Inc. (AMLX) 48.0 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 9, balance-sheet safety 55, capital discipline 24.

How has AMLX's Moat Score changed over time?

The record logs 1 reading since Jul 18, 2026; the latest reads 48.0 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Amylyx Pharmaceuticals, Inc.

AMLX · Healthcare · $2.0B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power99

Median gross margin 93.2% over 3y, very stable.

Returns on capital9

Median ROIC -105.6%, above the 9% hurdle in 25% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $17.75
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

6 years of fundamentals

The business, in plain English

It earned −154.1% on invested capital in FY2025, with a median of −105.6% across 4 filed years. The Returns on Capital filter above scores it 9/100.

AMLX's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the four filters (99/100) and Returns on Capital the weakest (9/100), which is how AMLX lands at 48/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$0 FY2025

Gross marginRevenue kept after cost of goods93.2% FY2024

Return on invested capitalOperating profit on the capital employed−154.1% FY2025

Owner earningsCash an owner could take out−$144.9M FY2025

Gaps in a line mean that item isn’t in AMLX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale48.0 / 100

Score history begins Jul 18, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — AMLX has read Shallow moat for every logged capture since Jul 18, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Track record

How Amylyx Pharmaceuticals, Inc.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

As-of Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored AMLX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, AMLX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#138 of 461 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#136CLDX Celldex Therapeutics, Inc.48.4 out of 100, Shallow moatShallow moat
#137NEPH NEPHROS, INC.48.0 out of 100, Shallow moatShallow moat
#139PAHC Phibro Animal Health Corporation47.9 out of 100, Shallow moatShallow moat
#140ONC BEONE MEDICINES LTD.47.9 out of 100, Shallow moatShallow moat

Compare AMLX with its nearest peers →All Healthcare companies on the Index →

Common questions about AMLX

Does Amylyx Pharmaceuticals, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Amylyx Pharmaceuticals, Inc. (AMLX) 48.0 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 99, returns on capital 9, balance-sheet safety 55, capital discipline 24.
How has AMLX's Moat Score changed over time?: The record logs 1 reading since Jul 18, 2026; the latest reads 48.0 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows AMLX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/AMLX"
  width="340" height="150" style="border:0"
  title="AMLX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell AMLX. See the disclaimer.